Joseph Canzoneri, DPM
Podiatrist · Batavia, NYNPI 1255309902
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,813 of the $9,280 with a category attached, or 62.6%. Smith+Nephew accounts for 77.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $7,198 and has fallen 96.2% since, to $271 in 2025. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $125.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$7K
- Misonix Inc$259
- Treace Medical Concepts, Inc.$248
- Cardiovascular Systems Inc.$246
- Musculoskeletal Transplant Foundation Inc.$212
- Paratek Pharmaceuticals, Inc.$210
- plus $902 from 14 others
What the payments were for
- Speaking & faculty fees$5,81363%
- Travel & lodging$89610%
- Food & beverage$2,57228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 20 | $7,204 |
| Misonix Inc | 8 | $259 |
| Treace Medical Concepts, Inc. | 7 | $248 |
| Cardiovascular Systems Inc. | 2 | $246 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $212 |
| Paratek Pharmaceuticals, Inc. | 14 | $210 |
| Organogenesis Inc. | 4 | $201 |
| Next Science LLC | 1 | $154 |
| W. L. Gore & Associates, Inc. | 1 | $115 |
| Kerecis Limited | 3 | $114 |
| Solventum Corporation | 1 | $79 |
| Philips North America LLC | 1 | $74 |
| Integra Lifesciences Corporation | 1 | $36 |
| KCI USA, Inc. | 2 | $24 |
| Tactile Systems Technology Inc | 1 | $24 |
| Paragon 28, Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Cashflow Solutions, LLC | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $12 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Santyl$6,796
- Xperience$154
- BlastX$154
- SurgX$154
- Diamondback Peripheral$126
- Lapiplasty System$120
- VIABAHN Endoprosthesis with Heparin Bioactive Surface$115
How this compares
$9,280 in reported general payments places this provider in the 95th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 65 | $34,544 |
| Ketoconazole | 396 | $7,271 |
| Febuxostat | 36 | $3,392 |
| Gabapentin | 323 | $2,735 |
| Clobetasol Propionate | 62 | $2,359 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 41 | $2,194 |
| Methylprednisolone | 211 | $1,695 |
| Doxycycline Hyclate | 174 | $1,616 |
| Econazole Nitrate | 38 | $1,511 |
| Doxycycline Monohydrate | 72 | $1,325 |
| Duloxetine Hcl | 59 | $1,183 |
| Terbinafine Hcl | 113 | $1,024 |
| Meloxicam | 243 | $988 |
| Cimetidine | 17 | $898 |
| Nitro-BidNitroglycerin | 15 | $575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $7,204 | $34,54465 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 862 podiatrist providers in New York.
Other podiatrist in Batavia
- Courtney FooteBatavia$10K
- Christopher BromleyPoughkeepsie$152K
- Scott GawlikBrooklyn$77K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
- Jude ViolanteNiagara Falls$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.